Uveal melanoma: ESMO–EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up

Uveal melanoma (UM) is associated with specific challenges due to its rare incidence. Optimal management of the disease requires multidisciplinary collaboration and coordination for the diagnosis, treatment, follow-up and support of patients at all stages and clearly established referral pathways.1 All patients should have access to centres with dedicated expertise in primary and metastatic UM either nationally or through cross-border access agreements, using the potential of the existing and forthcoming European Reference Networks as outlined in Europe’s Beating Cancer Plan, the ambition of the European Union (EU) Cancer Mission and the establishment and connection of Comprehensive Cancer Care Infrastructures in the EU.

Authors

Institutions

Publication Details

Journal
ESMO Open
Published
2026-04-01
DOI
https://doi.org/10.1016/j.esmoop.2026.106888
Primary Topic
Ocular Oncology and Treatments
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Uveal melanoma: ESMO–EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up

J.F. Baurain, S.E. Coupland, J.M. Piulats, S.P. Patel et al.
ESMO Open
Ocular Oncology and Treatments
article

Uveal melanoma: ESMO–EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up

J.F. Baurain, S.E. Coupland, J.M. Piulats, S.P. Patel, A. Fortuna, C. Gutierrez-Miguelez, R.M. Verdijk, J.J. Sacco, P.A. Ascierto, E. Kapiteijn, P. Nathan, A. Pica, A. Moulin, W. Sauerwein, O. Michielin, R. Dendale, B. Ryll, E. Kilic, M.C. Burgmans, M. Marinković, N. Cassoux, S. Piperno-Neumann, L. Gastaud, M. Angi, A. Valente, M.J. Jager, M. Schlaak, S. Heegaard, U. Keilholz, B. Stedman, C. Verhoef
article en

Abstract

Uveal melanoma (UM) is associated with specific challenges due to its rare incidence. Optimal management of the disease requires multidisciplinary collaboration and coordination for the diagnosis, treatment, follow-up and support of patients at all stages and clearly established referral pathways.1 All patients should have access to centres with dedicated expertise in primary and metastatic UM either nationally or through cross-border access agreements, using the potential of the existing and forthcoming European Reference Networks as outlined in Europe’s Beating Cancer Plan, the ambition of the European Union (EU) Cancer Mission and the establishment and connection of Comprehensive Cancer Care Infrastructures in the EU.

ESMO OpenVol. 11(4)
Champalimaud Foundation (PT), Leiden University (NL), Cliniques Universitaires Saint-Luc (BE), University of Liverpool (GB), Université Paris Cité (FR), Leiden University Medical Center (NL), Erasmus MC (NL), Paul Scherrer Institute (CH), Copenhagen University Hospital (DK), The Medical Center of Aurora (US), Rigshospitalet (DK), University Hospital Southampton NHS Foundation Trust (GB), Clatterbridge Cancer Centre NHS Foundation Trust (GB), Humboldt-Universität zu Berlin (DE), Hôpital Ophtalmique Jules-Gonin (CH), Sorbonne Paris Cité (FR), University Hospital of Geneva (CH), Institut Català d'Oncologia (ES), Mount Vernon Cancer Centre (GB), Centro Hospitalar Lisboa Norte (PT), NIHR Southampton Biomedical Research Centre (GB), Essen University Hospital (DE), Hospital Del Mar (ES), University of Colorado Cancer Center (US), Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT), Hospital de Santa Maria (PT), Erasmus MC Cancer Institute (NL), Centre Antoine Lacassagne (FR), Fondazione IRCCS Istituto Nazionale dei Tumori (IT), University of Colorado Anschutz Medical Campus (US), Charité - Universitätsmedizin Berlin (DE), Institut Curie (FR), University of Colorado Denver (US)
American Association for Cancer Research, Amgen, Pfizer, AstraZeneca, American Society of Clinical Oncology, Regeneron Pharmaceuticals, International Society of Ocular Oncology, Society for Immunotherapy of Cancer, Les Laboratories Pierre Fabre, BeiGene, Seagen, Astellas Pharma, European Society for Medical Oncology, Sun Pharma, Fundação Champalimaud, Qbiotics
Openalex Percentile: Top 29%
Ocular Oncology and Treatments
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.